A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis

NCT ID: NCT03688555

Last Updated: 2022-04-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-10-19
• Study Completion Date: 2020-12-01

Brief Summary

The study will evaluate the effect of ACT-774312 on the nasal polyps and will assess the safety and tolerability of ACT-774312 in the patients with bilateral nasal polyposis

Detailed Description

The clinical trial has 3 periods:

Screening and run-in period (4 Weeks). This period starts with the screening visit, and ends on Day 1, just before the first study treatment administration. At Visit 1, all participants will enter a run-in period of 4 weeks on mometasone furoate nasal spray of 2 actuations (50 μg per actuation) in each nostril twice daily (total daily dose of 400 μg), unless they were intolerant to twice daily intranasal corticosteroids, in which case they could use a lower dose regimen, i.e., 200 μg once daily.

Treatment period (ACT-774312 or placebo for 12 weeks). This period will start on Day 1 with the first administration of study treatment and consists of 4 visits: Week 2, Week 4, Week 8, and Week 12. Provided that the nasal polyp score (NPS) does not change during the run-in period, participants will be randomized to ACT-774312 (400 mg twice daily) or placebo (twice daily) for 12 weeks. During the double-blind randomized treatment all participants will continue with mometasone furoate nasal spray background therapy.

Post-treatment period (4 Weeks). This period will start after the Week 12 Visit and end at Week 16 (End-of-Study).

Conditions

Bilateral Nasal Polyposis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

ACT-774312

Participants will receive ACT-774312 (400 mg twice daily) in the morning and evening with or without food for 12 weeks together with mometasone furoate nasal spray.

Group Type: EXPERIMENTAL

ACT-774312

Intervention Type: DRUG

ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312

Placebo

Participants will receive placebo twice daily in the morning and evening with or without food for 12 weeks together with mometasone furoate nasal spray.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matching placebo hard gelatin capsules

Interventions

ACT-774312

ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312

Intervention Type: DRUG

Placebo

Matching placebo hard gelatin capsules

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Signed informed consent in the local language prior to any study mandated procedure.
• A minimum bilateral nasal polyp score (NPS) of 5 out of a maximum of 8 for both nostrils (with at least a score of 2 for each nostril) despite completion of a prior intranasal corticosteroids (INCS) treatment for at least 8 weeks before screening, with at least the 6 last weeks on INCS spray.
• Presence of at least 2 of the following symptoms at screening:

• nasal blockade/obstruction
• nasal discharge (anterior/posterior nasal drip)
• reduction or loss of smell.
• Male and female participants aged between 18 and 70 years (inclusive) at screening.
• Systolic blood pressure 90 to 160 mmHg, diastolic blood pressure 50 to 100 mmHg, pulse rate 45 to 100 bpm (inclusive), measured on the dominant arm, after 5 minutes in the supine position at screening.
• Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test pre-dose on Day 1. Women of childbearing potential must consistently and correctly use (from at least first dosing, during the entire study, and for at least 30 days after last study treatment intake) 1 highly effective method of contraception with a failure rate of less than 1% per year, be sexually abstinent, or have a vasectomized partner. Hormonal contraceptive must have been initiated at least 1 month before first study treatment administration.

Exclusion Criteria

• CYP2C9 poor metabolizer.
• Participant with severe renal function impairment (≤ 29 mL/min/1.73 m2) which is defined by estimated glomerular filtration rate at screening using the Modification of Diet in Renal Disease (MDRD) formula.
• Participant with Sino-Nasal Outcome Test (SNOT-22) less than 20.
• Participant who has required oral corticosteroids (OCS) within the 2 months before screening or is scheduled to receive OCS during the study period for another condition.
• Participant who has required INCS drops within the 6 weeks before screening.
• Participant who was injected with long-lasting activity corticosteroids within the 3 months before screening or is scheduled to receive these during the study period for another condition.
• Participant who has undergone any nasal surgery within 6 months before screening.
• Participant with conditions/concomitant diseases making them non-evaluable for the primary efficacy endpoint such as:

• Antrochoanal polyps
• Nasal septal deviation that occludes at least one nostril
• Acute sinusitis, nasal infection or upper respiratory infection at screening or in the 2 weeks before screening
• Ongoing rhinitis medicamentosa
• Churg-Strauss syndrome, Young's syndrome, Kartagener's syndrome or dyskinetic ciliary syndromes, Cystic fibrosis
• Signs or a CT scan suggestive of Allergic fungal rhinosinusitis.
• Participants with co-morbid asthma are excluded if:

• Forced expiratory volume in one second (FEV1) ≤ 60% of predicted normal OR
• An exacerbation requiring systemic (oral and/or parenteral) steroid treatment or hospitalization (>24 h) for treatment of asthma has occurred within 3 months prior screening OR
• They are on a dose higher than 1000 μg fluticasone or the equivalent of inhaled corticosteroids (ICS).
• Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
• Participants with active autoimmune disease (e.g., Hashimoto's thyroiditis, Graves' disease, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, psoriasis vulgaris, rheumatoid arthritis).
• Participant considered as vulnerable (e.g., sponsor or site employee, investigator subordinate, participant incapable of giving consent, participant committed to an institution by way of official or judicial order).
• Participant with liver injury related criteria:

• Underlying hepatobiliary disease OR
• Alanine aminotransferase greater than 3 x upper limit of normal, OR
• or Bilirubin greater than 2 x upper limit of normal.
• Participant with unstable NPS during the run-in period, i.e. altered score at Day 1 when compared to the screening NPS (assessed locally by the investigator).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Idorsia Pharmaceuticals Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Idorsia Pharmaceuticals Ltd.

Locations

University Hospital Ghent

Ghent, , Belgium

Charité Research Organisation GmbH

Berlin, , Germany

Countries

Belgium; Germany

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

2018-000851-42

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ID-084A201

Identifier Type: -

Identifier Source: org_study_id